Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
10Customers
3Debt Items
7Related Chains
Source-Backed Evidence Depth
ABVC BioPharma, Inc. (ABVC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
1Distinct source URLs
10High confidence
0.760Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
ABVC BioPharma, Inc. Suppliers
Ticker
Name
Confidence
Evidence
AIBTL-BIOPHARMA-INC
AIBTL-BIOPHARMA-INC
90%
License Agreement between the Company and AiBtl BioPharma Inc.
BIOFIRST-CORPORATION
BIOFIRST-CORPORATION
90%
Definitive License Agreement between BioFirst Corporationand ForSeeCon Eye Corporation
BIOLITE-INC
BIOLITE-INC
90%
Definitive License Agreement between Biolite, Inc. and OncoX BioPharma, Inc.
FORSEECON-EYE-CORPORATION
FORSEECON-EYE-CORPORATION
90%
Definitive License Agreement between the Company and ForSeeCon Eye Corporation
ONCOX-BIOPHARMA-INC
ONCOX-BIOPHARMA-INC
90%
Definitive License Agreement between the Company and OncoX BioPharma, Inc.
RGENE
RGENE
90%
Definitive License Agreement between Rgene and OncoX BioPharma, Inc.
ABVC BioPharma, Inc. Customers
Ticker
Name
Confidence
Evidence
AIBTL-BIOPHARMA-INC
AIBTL-BIOPHARMA-INC
62%
Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Form 10-Q that does not consist of historical facts, are “forward-looking statem…
BRIVISION-BIOLITE-HOLDING-INC
BRIVISION-BIOLITE-HOLDING-INC
62%
Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Form 10-Q that does not consist of historical facts, are “forward-looking statem…
COMPANY-LUCIDAIM-CO-LTD
COMPANY-LUCIDAIM-CO-LTD
62%
In February and December of 2015, BioLite, Inc. entered into a total of three joint venture agreements with BioHopeKing to jointly develop ABV-1501 for Triple Negative Breast Cancer (TNBC), ABV-1504 …
FORSEECON-EYE-CORPORATION
FORSEECON-EYE-CORPORATION
62%
eement upon certain defaults committed by another Shareholder, as set forth in the Agreement. This was a related party transaction. In 2024, the Company recognized fully $150,000 loss in equity metho…
GROUP-THE-GROUP
GROUP-THE-GROUP
62%
anagement approach to determine operating segments. The management approach considers the internal organization and reporting used by the Group’s chief operating decision maker (“CODM”) for making de…
Reciprocal relationship from LCID graph: Reciprocal relationship from ABVC graph: Reciprocal relationship from LCID graph: Reciprocal relationship from ABVC graph: Reciprocal relationship from LCID g…
ONCOX-BIOPHARMA-INC
ONCOX-BIOPHARMA-INC
62%
e candidates from large research institutes and universities in both the U.S. and Taiwan. Through an assertive product development approach, we expect that we will build a substantial portfolio of On…
ONCOX-BIOPPHARMA-INC
ONCOX-BIOPPHARMA-INC
62%
e candidates from large research institutes and universities in both the U.S. and Taiwan. Through an assertive product development approach, we expect that we will build a substantial portfolio of On…
OVERVIEW-ABVC-BIOPHARMA-INC
OVERVIEW-ABVC-BIOPHARMA-INC
62%
Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Form 10-Q that does not consist of historical facts, are “forward-looking statem…
TAIWAN-CENTRAL-DEPOSIT-INSURANCE-CORPORATION
TAIWAN-CENTRAL-DEPOSIT-INSURANCE-CORPORATION
62%
y be in excess of the limit of $ 95,400 (NTD 3.0 million) covered by Taiwan Central Deposit Insurance Corporation, and the limit of $ 250,000 covered by the U.S. Federal Deposit Insurance Corporation…
ABVC BioPharma, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ABVC-DEBT-7446
Warrants outstanding: 500000
90%
xbrl warrant detail from xbrl 2025-12-31.
ABVC-DEBT-7447
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
ABVC-DEBT
Debt stack $3.5M
90%
Market cache reports total debt of $3.5M.
ABVC BioPharma, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for ABVC BioPharma, Inc..
ABVC BioPharma, Inc. Ownership
Holder
Name
Confidence
Evidence
ABVC-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 15 tracked holders.
ABVC BioPharma, Inc. Extended Supply Chain Network
